Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review

Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review

Background: Targeting epidermal growth factor receptors (EGFR) is an innovative approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation. However, the efficacy of these agents like erlotinib in patients without the mutation is not known. Methods: This systematic review in...

Full description

Bibliographic Details
Main Authors: Abdul-Rahman Jazieh, Reem Al Sudairy, Nada Abu-Shraie, Wafaa Al Suwairi, Mazen Ferwana, M Hassan Murad
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Annals of Thoracic Medicine
Subjects:
Epidermal growth factor
erlotinib
non-small cell lung cancer
Online Access:http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2013;volume=8;issue=4;spage=204;epage=208;aulast=Jazieh

Internet

http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2013;volume=8;issue=4;spage=204;epage=208;aulast=Jazieh

Similar Items